(19)
(11) EP 2 365 065 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A2)

(48) Corrigendum issued on:
23.11.2011 Bulletin 2011/47

(43) Date of publication:
14.09.2011 Bulletin 2011/37

(21) Application number: 10012255.5

(22) Date of filing: 03.10.2006
(27) Previously filed application:
 03.10.2006 PCT/IB20/06003883
(51) International Patent Classification (IPC): 
C12N 9/22(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 25.10.2005 WO PCT/IB2005/003564

(62) Application number of the earlier application in accordance with Art. 76 EPC:
06842325.0 / 1954807

(71) Applicant: Cellectis
93235 Romainville Cedex (FR)

(72) Inventor:
  • Paques, Frédéric
    92340 Bourg-La-Reine (FR)

(74) Representative: Noel, Chantal Odile et al
Cabinet Orès 36, rue de St Pétersbourg
75008 Paris
75008 Paris (FR)

 
Remarks:
Claims filed after the date of receipt of the divisional application (Rule 68(4) EPC).
Remarks:
This application was filed on 30-09-2010 as a divisional application to the application mentioned under INID code 62.
 


(54) I-Crel homing endonuclease variants having novel cleavage specificity and use thereof


(57) A method for engineering I-CreI homing endonuclease variants able to cleave mutant I-CreI sites having variation in positions ± 8 to ±10. A I-CreI homing endonuclease variant obtainable by said method, a vector encoding said variant, a cell, an animal or a plant modified by said vector. Use of said I-CreI endonuclease variant and derived products for genetic engineering, genome therapy and antiviral therapy.